SkinBioTherapeutics logo

SBTX - SkinBioTherapeutics Share Price

39.1p -3.2  -7.5%

Last Trade - 4:29pm

Sector
Healthcare
Size
Small Cap
Market Cap ÂŁ65.9m
Enterprise Value ÂŁ63.7m
Revenue ÂŁn/a
Position in Universe 1146th / 1807
Bullish
Bearish
Unlock SBTX Revenue
Momentum
Relative Strength (%)
1m +4.74%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.06%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 0.29
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020,Skinbiotherapeutics PLC revenues was not reported. Net lossincreased 31% to ÂŁ1.5M. Higher net loss reflects Operatingexpenses increase of 51% to ÂŁ985K (expense). Basic Earningsper Share excluding Extraordinary Items remained flat at-ÂŁ0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SBTX
Graphical History

Revenue

SBTX Revenue Unlock SBTX Revenue

Net Income

SBTX Net Income Unlock SBTX Revenue

Normalised EPS

SBTX Normalised EPS Unlock SBTX Revenue

PE Ratio Range

SBTX PE Ratio Range Unlock SBTX Revenue

Dividend Yield Range

SBTX Dividend Yield Range Unlock SBTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SBTX EPS Forecasts Unlock SBTX Revenue
Profile Summary

SkinBioTherapeutics PLC is a life science company focused on skin health. The Company’s platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company’s SkinBiotix platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. It focuses on three specific skin healthcare sectors: cosmetics, infection control and eczema. In each of these areas, the Company plans to exemplify its technology in human studies. The Company’s program is focused on the application of the Skinbiotix platform in managing sensitive skin in the cosmetics industry. SkinBiotix increases the rate of skin healing in response to injury.

Directors
Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated June 10, 2015
Public Since April 5, 2017
No. of Shareholders: n/a
No. of Employees: 7
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 155,889,922
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SBTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SBTX
Upcoming Events for SBTX
Frequently Asked Questions for SkinBioTherapeutics
What is the SkinBioTherapeutics share price?

As of 4:29pm, shares in SkinBioTherapeutics are trading at 39.1p, giving the company a market capitalisation of ÂŁ65.9m. This share price information is delayed by 15 minutes.

How has the SkinBioTherapeutics share price performed this year?

Shares in SkinBioTherapeutics are currently trading at 39.1p and the price has moved by 0.277k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the SkinBioTherapeutics price has moved by 0.276k% over the past year.

What are the analyst and broker recommendations for SkinBioTherapeutics?

There are no analysts currently covering SkinBioTherapeutics.

When will SkinBioTherapeutics next release its financial results?

SkinBioTherapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the SkinBioTherapeutics dividend yield?

SkinBioTherapeutics does not currently pay a dividend.

Does SkinBioTherapeutics pay a dividend?

SkinBioTherapeutics does not currently pay a dividend.

When does SkinBioTherapeutics next pay dividends?

SkinBioTherapeutics does not currently pay a dividend.

How do I buy SkinBioTherapeutics shares?

To buy shares in SkinBioTherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of SkinBioTherapeutics?

Shares in SkinBioTherapeutics are currently trading at 39.1p, giving the company a market capitalisation of ÂŁ65.9m.

Where are SkinBioTherapeutics shares listed? Where are SkinBioTherapeutics shares listed?

Here are the trading details for SkinBioTherapeutics:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: SBTX
What kind of share is SkinBioTherapeutics?

Based on an overall assessment of its quality, value and momentum, SkinBioTherapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a SkinBioTherapeutics share price forecast 2021?

We were not able to load any forecast data for SkinBioTherapeutics.

How can I tell whether the SkinBioTherapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SkinBioTherapeutics. Over the past six months, the relative strength of its shares against the market has been 65.09%. At the current price of 39.1p, shares in SkinBioTherapeutics are trading at 95.57% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the SkinBioTherapeutics PE Ratio?

We were not able to find PE ratio data for SkinBioTherapeutics.

Who are the key directors of SkinBioTherapeutics?

SkinBioTherapeutics's management team is headed by:

Martin Hunt - NEC
Douglas Quinn - CFO
Catherine Prescott - NID
Stuart Ashman - CEO
Who are the major shareholders of SkinBioTherapeutics?

Here are the top five shareholders of SkinBioTherapeutics based on the size of their shareholding:

OptiBiotix Health Plc Corporation
Percentage owned: 24.47% (38.1m shares)
Seneca Partners Ltd. Corporation
Percentage owned: 11.79% (18.4m shares)
University of Manchester Corporation
Percentage owned: 5.13% (8.00m shares)
ONeill (Catherine) Individual Investor
Percentage owned: 3.37% (5.26m shares)
Tyndall Investment Management Ltd. Investment Advisor
Percentage owned: 3.05% (4.75m shares)
Similar to SBTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.